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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
c o r r e s p o n d e n c e
Enzalutamide in Prostate Cancer after Chemotherapy
To the Editor: In the randomized trial reported 
by Scher et al. (Sept. 27 issue),1 the administration 
of enzalutamide, an androgen-receptor–signaling 
inhibitor, was associated with an increased inci-
dence of headache, as compared with placebo, in 
patients with castration-resistant prostate cancer. 
Androgens are implicated in the pathogenesis of 
migraine; thus, it is important to understand 
whether the headache associated with enzaluta-
mide could be classified as migraine. Moreover, 
a deeper understanding of the pathophysiology 
of this side effect is clinically relevant, since a 
relationship between migraine and the presence 
of either hot flashes or seizures has been de-
scribed previously.2,3 Migraine and epilepsy have 
pathophysiological characteristics in common,3 
so patients who have migraine during enzaluta-
mide therapy may be at increased risk for sei-
zures. Notably, headache was not reported as a 
clinically relevant symptom in patients with cas-
tration-resistant prostate cancer who received 
abirater one,4 a drug that deeply reduces circulat-
ing androgen levels. Abiraterone was adminis-
tered in association with prednisone, and glucocor-
ticoids are efficacious in preventing migraine.5 It 
would be interesting to know whether glucocor-
ticoids were used in the management of enzalu-
tamide-induced headache and whether they 
were effective.
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The Authors Reply: In AFFIRM (A Study Evalu-
ating the Efficacy and Safety of the Investigation-
al Drug MDV3100), data on the adverse events of 
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migraine and headache were collected separately. 
Of the 800 patients treated with enzalutamide, 
3 (0.4%) were reported to have had a migraine. 
Headaches were reported in 93 patients treated 
with enzalutamide (11.6%) and in 22 of the 399 
patients treated with placebo (5.5%). In the en-
zalutamide group, the majority of reports were 
for grade 1 headache that did not require treat-
ment. No patient was treated for headache with 
glucocorticoids. One patient reporting seizure in 
AFFIRM reported a headache 5 months before 
the report of seizure.
Berruti et al. state that headaches were not 
reported as a relevant symptom in patients re-
ceiving abiraterone acetate plus prednisone in a 
recent phase 3 study.1 However, the clinical re-
view of abiraterone acetate by the Food and Drug 
Administration (new drug application number, 
202379) reported a similar frequency of headache 
in the two study groups (11.9% of patients in the 
abiraterone-plus-prednisone group and 10.7% of 
those in the placebo-plus-prednisone group).2
Overall, these data do not support the sug-
gestion by Berruti et al. that the headaches 
observed in the enzalutamide study reflect mi-
graines, nor that patients who had a headache 
during treatment with enzalutamide are at in-
creased risk for seizure.
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Understanding Low Sugar from NICE-SUGAR
To the Editor: In his editorial about the Normo-
glycemia in Intensive Care Evaluation–Survival Us-
ing Glucose Algorithm Regulation (NICE-SUGAR) 
study,1 Hirsch (Sept. 20 issue)2 declares, “For sur-
gical patients, especially those who have under-
gone cardiac procedures, hospitals that can safely 
achieve lower targets should do so.” No justifica-
tion for this statement is provided. Concerns ex-
ist regarding the generalizability of studies of 
glycemic control in other populations of patients 
treated in intensive care units (ICUs) that have 
shown either harm1 or no benefit3 and regarding 
both the generalizability and applicability of stud-
ies that have shown benefit.4 Accordingly, the ef-
fect of maintaining the blood sugar levels of sur-
gical patients admitted to the ICU below those of 
the control group in the NICE-SUGAR study1 re-
mains uncertain. We believe the targeting of blood 
glucose levels below that of the control group in 
this study should occur only in the context of 
well-designed clinical trials. To do otherwise ex-
poses surgical patients admitted to the ICU to a 
therapy of uncertain benefit and that is associ-
ated with harm in other ICU patient populations. 
It also promotes the inefficient use of valuable 
health care resources at a time when the Journal is 
fostering debate around this challenging issue.5
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The editorialist replies: French and McGain 
bring up an important point. The most recent 
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